Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen counts on Kairos Expertise in Biobank- Management

Published: Friday, March 30, 2012
Last Updated: Friday, March 30, 2012
Bookmark and Share
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.

"Protagen has established an industrial standard for automated highthroughput expression of recombinant human proteins and their respective use for biomarker development and clinical validation. In addition, we have built an excellent and unique network of internationally renowned clinical partners in all relevant indication areas”, explains Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen. „The expertise of Kairos will complement our technology position. In addition, it will support our collaborations with drug development companies in a very efficient way and will allow for more effective project and study management.”

Martin Zünkeler, founder and General Manager of Kairos adds "Decisive for the partnership with Protagen was the high grade of automation established in the labs, and the overall high quality of the processes employed. For instance, the fully automated aliquotation with latest robotic systems is already daily routine at Protagen. By and large, this is an ideal situation to adapt and develop software solutions for study management and biobanking”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test
BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).
Thursday, June 16, 2016
Using Biomarkers to Identify Inflammation in Prostate Cancer Patients
Discovery of new biomarkers for chronic inflammation could allow the development of new, more accurate prostate cancer diagnostics.
Wednesday, March 30, 2016
Novel Route to Serum Based Prostate Cancer Diagnostics
Protagen AG has announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.
Thursday, February 11, 2016
Protagen AG Joins RA-MAP Consortium
Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has announced that it will join the RA-MAP Consortium.
Thursday, January 21, 2016
Protagen, Mikrogen Collaborate
Protagen and Mikrogen have agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.
Friday, November 13, 2015
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen at the European Antibody Congress 2010
Company experts will present the characterization of biotherapeutics with protein microarrays and the latest developments of GMP-compliant protein analysis.
Wednesday, November 03, 2010
Protagen Raises € 10.0 Million for Diagnostic Developments
Funds will be utilized for the targeted expansion of the business unit Diagnostics and the clinical validation of proprietary diagnostic marker proteins.
Thursday, September 09, 2010
Key Patent of Protagen Granted in Japan
The patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology.
Friday, August 13, 2010
Protagen Deepens Cooperation with Bayer Schering Pharma
Both the companies announce the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.
Thursday, June 10, 2010
Protagen Raises €1 Million to Expand its Protein Biochips Business Unit
Protagen’s UNIchip® protein biochip range has experienced increasing demand from biotech and pharmaceutical companies in the USA and Europe.
Friday, January 18, 2008
Protagen Expands to the USA
With the formation of the American subsidiary Protagen responds to the increasing demand of protein biochips for validation of antibodies produced in Dortmund.
Monday, September 25, 2006
Protagen Strengthens its Management Team
Jens Beator is now responsible for the technical development of the UNIchip® family within Protagen.
Thursday, September 21, 2006
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Nanoprobe Enables Measurement of Protein Dynamics in Living Cells
Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!